I agree that is what he posted, but it was before the trial was announced, so he was clearly talking about an abstract regitstrational trial and not the actual design.
I certainly highly respect dewophile. He clearly has an expert knowledge of the clinical aspects of this field (whereas I have none). I consider his input exceptionally valuable in guestimating a valuation. If he is correct, the DD's 36% number STILL makes this stock a buy.
Market Data 
Markets 
AI
